Trade Regulation

ORS 646A.697
Study of market for generic drugs

  • effect of pricing on insurance premiums
  • report to Legislative Assembly


As used in this section, “generic drug” means:


A retail drug that is marketed or distributed in accordance with an abbreviated new drug application approved under 21 U.S.C. 355(j);


An authorized generic as defined by 42 C.F.R. 447.502; or


A drug that entered the market before 1962 that was not originally marketed under a new drug application.


The Prescription Drug Affordability Board shall annually conduct a study of the operation of the United States market for generic drugs, both drugs dispensed by pharmacists and drugs administered by physicians, including:


The prices of generic drugs on a year-to-year basis;


The degree to which generic drug prices affect insurance premiums;


Annual changes in health insurance cost-sharing for generic drugs;


The potential for and history of generic drug shortages;


The degree to which generic drug prices affect annual spending in the state medical assistance program; and


Any other topic the board considers relevant to the cost of generic drugs.


No later than June 1 of each calendar year, the board shall report to the Legislative Assembly the findings of the board’s study in the manner provided in ORS 192.245 (Form of report to legislature). [2021 c.598 §6]
(Foreclosure Consultants)


Last accessed
May 26, 2023